Abstract
Pseudomonas aeruginosa (PA) is a major cause of nosocomial infections, which remain an unsolved problem in the clinic despite conventional antibiotic treatment. A PA vaccine could be both an effective and economical strategy to address this issue. Many studies have shown that PcrV, a structural protein of the type 3 secretion system (T3SS) from PA, is an ideal target for immune prevention and therapy. However, difficulties in the production of high-quality PcrV likely hinder its further application in the vaccine industry. Thus, we hypothesized that an optimized PcrV derivative with a rational design could be produced. In this study, the full-length PcrV was divided into four domains with the guidance of its structure, and the Nter domain (Met1-Lys127) and H12 domain (Leu251-Ile294) were found to be immunodominant. Subsequently, Nter and H12 were combined with a flexible linker to generate an artificial PcrV derivative (PcrVNH). PcrVNH was successfully produced in E. coli and behaved as a homogenous monomer. Moreover, immunization with PcrVNH elicited a multifactorial immune response and conferred broad protection in an acute PA pneumonia model and was equally effective to full-length PcrV. In addition, passive immunization with anti-PcrVNH antibodies alone also showed significant protection, at least based on inhibition of the T3SS and mediation of opsonophagocytic killing activities. These results provide an additional example for the rational design of antigens and suggest that PcrVNH is a promising vaccine candidate for the control of PA infection.
Highlights
Pseudomonas aeruginosa (PA) is a major cause of nosocomial infections in patients with compromised immunity [1]
Antigen-specific antibodies are responsible for vaccine-induced protection; we investigated whether passive immunization of anti-PcrVNH antibodies alone was protective
The results showed that the amount of secreted ExoU in both inducing and non-inducing conditions were reduced with the increase in anti-PcrVNH antibodies, while there was no change in non-specific rabbit IgGs at a concentration as high as 10 mg/ml (Figure 5C)
Summary
Pseudomonas aeruginosa (PA) is a major cause of nosocomial infections in patients with compromised immunity [1]. In patients with impaired respiratory functions, PA-induced pneumonia contributes to a larger proportion of mortality, such as from cystic fibrosis [2], long-term mechanical ventilation [3], and COPD [4]. The effectiveness of antibiotic therapies is limited. It remains difficult to combat PA infection despite supportive treatments. Vaccines could be an alternative strategy to control PA infections and even reduce antibiotic resistance; no PA vaccine is currently available [5].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
